MDM2 and cancer: This is evidenced by studies that have shown that USP7 inhibitor treatment accelerated the proteasomal degradation of MDM2 and MDMX in cancer cells, which negatively regulate p53, thereby activating p53 and its downstream target p21, resulting in cell cycle arrest and apoptosis [7, 41, 58].